Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Andreas Kristo
Andreas Kristo

Tyra Biosciences begins dosing in Phase 2 trial for dabogratinib in low grade UTUC

Tyra Biosciences begins dosing in Phase 2 trial for dabogratinib in low grade UTUC
Tyra starts Phase 2 cancer trial

Tyra Biosciences has announced the dosing of the first patient in its Phase 2 clinical trial for SURF303, assessing the investigational oral FGFR3-selective inhibitor dabogratinib in low grade upper tract urothelial carcinoma (UTUC).

The once-daily oral therapy targets patients with LG-UTUC, a rare form of urinary tract cancer. This study marks a significant step in evaluating new treatment options for a patient group with limited therapies.

Tyra Biosciences has recently expanded its oncology pipeline. The company previously partnered with KUMedCenter to support the SURF302 clinical trial advancing bladder cancer research. The latest Phase 2 study adds to its ongoing efforts targeting rare urothelial cancers.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Global fintech in 2026: Three trends that matter
  • By Pavlo Kot
  • 22 hours ago
Global fintech in 2026: Three trends that matter
Editors' Picks
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
  • By Pavlo Kot
  • Yesterday
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
Editors' Picks
Hunting crypto owners: Why criminals have gone offline
  • By Andrey Mastykin
  • 25.07.2026
Hunting crypto owners: Why criminals have gone offline
Editors' Picks
All Editors' Top Picks

Latest Tyra News

Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC
  • By Eugene Komchuk
  • 24.07.2026
Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC
Companies
#Tyra
Tyra Biosciences pursues new treatment strategies for urologic cancers
  • By Jose Antonio Gastelum
  • 22.07.2026
Tyra Biosciences pursues new treatment strategies for urologic cancers
Companies
#Tyra
Tyra Biosciences initiates partnership with KUMedCenter to advance SURF302 bladder cancer trial
  • By Oleg Tkachenko
  • 05.05.2026
Tyra Biosciences initiates partnership with KUMedCenter to advance SURF302 bladder cancer trial
Companies
#Tyra
All Tyra News
  • Pavlo Kot
  • 22 hours ago
Global fintech in 2026: Three trends that matter
  • Pavlo Kot
  • Yesterday
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
  • Andrey Mastykin
  • 25.07.2026
Hunting crypto owners: Why criminals have gone offline
  • Eugene Komchuk
  • 24.07.2026
BitMEX is shutting down: Why Trump could not save the exchange
  • Anastasiia Chabaniuk
  • 24.07.2026
Do governments need crypto workers?
  • Jose Antonio Gastelum
  • 1 hour ago
Holding altcoins only in confirmed bull trends drives returns, Ivan Liljeqvist argues
  • Andrey Mastykin
  • 1 hour ago
Willem Middelkoop: Fed has prioritized price stability since 1913
  • Oleg Tkachenko
  • 1 hour ago
Quantitative easing likely to resume with intensity, Frank Giustra predicts
  • Daria Chernytska
  • 1 hour ago
Pushpendra Singh: India sets new crypto reporting framework for exchanges
  • Yaroslav Dmytrenko
  • 2 hours ago
Bitcoin tests $65,700 resistance after rebound, Jordan Kerridge notes
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Ivan Andriyenko
  • 13 min ago
Nvidia considers $250 billion support for OpenAI project
Nvidia considers $250 billion support for OpenAI project
  • Hanna Syniavska
  • 1 hour ago
Brent falls below $90 as Middle East tensions ease
Brent falls below $90 as Middle East tensions ease
  • Eugene Komchuk
  • 1 hour ago
Storj Labs files for bankruptcy
Storj Labs files for bankruptcy
  • Pavlo Kot
  • 22 hours ago
Global fintech in 2026: Three trends that matter
Global fintech in 2026: Three trends that matter
  • Pavlo Kot
  • Yesterday
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
From Jesus Christ to aliens: Polymarket's most absurd prediction markets
Live News
  • Mykhailo Ihnatenko
  • Now
Solana price follows crypto rebound but volume remains weak
  • Mykhailo Ihnatenko
  • Now
Ethereum price eyes $2,000 as U.S.-Iran tensions ease
  • Anton Kharitonov
  • Now
Microsoft steadies after selloff as AI fundamentals remain intact
  • Anton Kharitonov
  • Now
Apple outperforms broader market as investors seek quality amid volatility
  • Anton Kharitonov
  • Now
Bitcoin breaks key support as broad selloff accelerates
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR